Original Article Online Publishing Date: | ||||||||||||
IJMDC. 2021; 5(10): 1716-1721 Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients Abdulatif Al Mulhim, Abdulwahab Alyahya, Yasser Ghazi S Alarimah, Mohammed Alayed, Alaa Alyahyawi, Abdul Ali Peer Zada.
|
How to Cite this Article |
Pubmed Style Mulhim AA, Alyahya A, Alarimah YGS, Alayed M, Alyahyawi A, Zada AAP. Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients. IJMDC. 2021; 5(10): 1716-1721. doi:10.24911/IJMDC.51-1627255589 Web Style Mulhim AA, Alyahya A, Alarimah YGS, Alayed M, Alyahyawi A, Zada AAP. Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients. https://www.ijmdc.com/?mno=101650 [Access: March 26, 2024]. doi:10.24911/IJMDC.51-1627255589 AMA (American Medical Association) Style Mulhim AA, Alyahya A, Alarimah YGS, Alayed M, Alyahyawi A, Zada AAP. Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients. IJMDC. 2021; 5(10): 1716-1721. doi:10.24911/IJMDC.51-1627255589 Vancouver/ICMJE Style Mulhim AA, Alyahya A, Alarimah YGS, Alayed M, Alyahyawi A, Zada AAP. Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients. IJMDC. (2021), [cited March 26, 2024]; 5(10): 1716-1721. doi:10.24911/IJMDC.51-1627255589 Harvard Style Mulhim, A. A., Alyahya, . A., Alarimah, . Y. G. S., Alayed, . M., Alyahyawi, . A. & Zada, . A. A. P. (2021) Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients. IJMDC, 5 (10), 1716-1721. doi:10.24911/IJMDC.51-1627255589 Turabian Style Mulhim, Abdulatif Al, Abdulwahab Alyahya, Yasser Ghazi S Alarimah, Mohammed Alayed, Alaa Alyahyawi, and Abdul Ali Peer Zada. 2021. Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients. International Journal of Medicine in Developing Countries, 5 (10), 1716-1721. doi:10.24911/IJMDC.51-1627255589 Chicago Style Mulhim, Abdulatif Al, Abdulwahab Alyahya, Yasser Ghazi S Alarimah, Mohammed Alayed, Alaa Alyahyawi, and Abdul Ali Peer Zada. "Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients." International Journal of Medicine in Developing Countries 5 (2021), 1716-1721. doi:10.24911/IJMDC.51-1627255589 MLA (The Modern Language Association) Style Mulhim, Abdulatif Al, Abdulwahab Alyahya, Yasser Ghazi S Alarimah, Mohammed Alayed, Alaa Alyahyawi, and Abdul Ali Peer Zada. "Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients." International Journal of Medicine in Developing Countries 5.10 (2021), 1716-1721. Print. doi:10.24911/IJMDC.51-1627255589 APA (American Psychological Association) Style Mulhim, A. A., Alyahya, . A., Alarimah, . Y. G. S., Alayed, . M., Alyahyawi, . A. & Zada, . A. A. P. (2021) Treatment response to tyrosine kinase inhibitors (imatinib vs. dasatinib) and its link to vitamin D deficiency among adult CML patients. International Journal of Medicine in Developing Countries, 5 (10), 1716-1721. doi:10.24911/IJMDC.51-1627255589 |